Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4271959 | 0.94 | DNM1 (0.41) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL4276525 | 0.92 | OPRM1 (0.46) | DNM1TSHROPRM1CA1ADH1B | |
| SCHEMBL4275343 | 0.90 | OPRM1 (0.44) | DNM1TSHROPRM1CA1ADH1B | |
| SCHEMBL4271944 | 0.90 | OPRM1 (0.44) | DNM1TSHROPRM1CA1ADH1B | |
| SCHEMBL4272618 | 0.90 | OPRM1 (0.44) | DNM1TSHROPRM1CA1ADH1B | |
| SCHEMBL4277169 | 0.89 | OPRM1 (0.48) | DNM1TSHRSMN1; SMN2OPRM1CA2 | |
| SCHEMBL4269676 | 0.88 | TSHR (0.38) | TSHROPRM1ALDH1A1TDP1CYP3A4 | |
| SCHEMBL4276657 | 0.86 | DNM1 (0.48) | DNM1TSHROPRM1CA2ADH1B | |
| SCHEMBL1874459 | 0.86 | DNM1 (0.48) | DNM1TSHROPRM1CA2ADH1B | |
| SCHEMBL4273909 | 0.86 | DNM1 (0.48) | DNM1TSHROPRM1CA2ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976085-B2 | Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis | Aperion Synthesis S.A. (PL) | 2024-05-07 | — | — | US | disclosed |
| WO-2024052871-A1 | NOVEL RUTHENIUM COMPLEXES, METHOD OF THEIR SYNTHESIS, INTERMEDIATE COMPOUNDS USED IN THIS METHOD, METHOD OF THEIR SYNTHESIS AND USE OF NOVEL RUTHENIUM COMPLEXES IN OLEFIN METATHESIS REACTIONS | UNIWERSYTET WARSZAWSKI (PL) | 2024-03-14 | — | — | WO | disclosed |
| US-20240076308-A1 | PROCESS FOR PRODUCING RUTHENIUM COMPLEXES AND INTERMEDIATES THEREOF AND THEIR USE IN OLEFIN METATHESIS | APEIRON SYNTHESIS SA (PL) | 2024-03-07 | — | — | US | disclosed |
| WO-2023248205-A1 | NOVEL RUTHENIUM COMPLEXES, METHOD OF THEIR SYNTHESIS, INTERMEDIATE COMPOUNDS USED IN THIS METHOD, METHOD OF THEIR SYNTHESIS AND THE USE OF NOVEL RUTHENIUM COMPLEXES IN OLEFIN METATHESIS REACTIONS | UNIWERSYTET WARSZAWSKI (PL) | 2023-12-28 | — | — | WO | disclosed |
| US-20230322830-A1 | Novel ruthenium complexes, methods of their preparation and application thereof in olefin cross metathesis | APEIRON SYNTHESIS S.A. (PL) | 2023-10-12 | — | — | US | disclosed |
| US-20230295215-A1 | NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2023-09-21 | — | — | US | disclosed |
| WO-2023135582-A1 | NEW STEREORETENTIVE RUTHENIUM COMPLEXES, METHOD OF THEIR PREPARATION, INTERMEDIATES USED IN THIS METHOD AND USE OF NEW STEREORETENTIVE RUTHENIUM COMPLEXES IN OLEFIN METATHESIS REACTIONS | UNIWERSYTET WARSZAWSKI (PL) | 2023-07-20 | — | — | WO | disclosed |
| EP-3820609-B1 | USE OF N-CHELATING RUTHENIUM COMPLEXES IN THE METATHESIS REACTION | APEIRON SYNTHESIS SA (PL) | 2023-06-28 | — | — | EP | disclosed |
| EP-4196267-A1 | NOVEL RUTHENIUM COMPLEXES, METHODS OF THEIR PREPARATION AND APPLICATION THEREOF IN OLEFIN CROSS METATHESIS | Apeiron Synthesis S.A. (PL) | 2023-06-21 | — | — | EP | disclosed |
| US-20230130423-A1 | NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2023-04-27 | — | — | US | disclosed |
| WO-2013046108-A1 | RUTHENIUM OR OSMIUM COMPLEX, METHOD FOR ITS PREPARATION AND USE THEREOF | Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) | 2013-04-04 | — | — | WO | disclosed |
| WO-2012168395-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2012-12-13 | — | — | WO | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-12-23 | — | — | US | disclosed |
| WO-2010117796-A2 | PROCESSES FOR THE PREPARATION OF ALPHA-CHLOROKETONES FROM CARBOXYLIC ACIDS | CODEXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-2239261-A1 | PYRROLOPYRIMIDIN DERIVATIVE FOR USE AS PI3K INHIBITOR, AND USE THEREOF | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009037283-A1 | METHOD FOR PRODUCING SUBSTRATES COATED WITH RYLENE TETRACARBOLIC ACID DIIMIDES | BASF SE (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-20090078312-A1 | VERFAHREN ZUR HERSTELLUNG VON MIT RYLENTETRACARBONSAEUREDIIMIDEN BESCHICHTETEN SUBSTRATEN | BASF SE (DE) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130423-A1 | NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | RNGTT, RNMT, NSUN3 | DNM1 1458/4885TSHR 3206/4885SMN1; SMN2 2698/4885 |
| US-20230322830-A1 | Novel ruthenium complexes, methods of their preparation and application thereof in olefin cross metathesis | CYP4F11, CYP4F3, CYP4F12 | DNM1 2311/4885TSHR 4763/4885SMN1; SMN2 4429/4885 |
| US-11976085-B2 | Process for producing ruthenium complexes and intermediates thereof and their use in olefin metathesis | POR, CYP1B1, CYP4F11 | DNM1 378/4885TSHR 4724/4885SMN1; SMN2 4510/4885 |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | DNM1 2245/4885TSHR 3412/4885SMN1; SMN2 3098/4885 |
| US-20090078312-A1 | VERFAHREN ZUR HERSTELLUNG VON MIT RYLENTETRACARBONSAEUREDIIMIDEN BESCHICHTETEN SUBSTRATEN | AXIN2, NCSTN, NES | DNM1 1249/4885TSHR 3585/4885SMN1; SMN2 3380/4885 |
| US-20240076308-A1 | PROCESS FOR PRODUCING RUTHENIUM COMPLEXES AND INTERMEDIATES THEREOF AND THEIR USE IN OLEFIN METATHESIS | POR, CYP1B1, CYP4F11 | DNM1 378/4885TSHR 4724/4885SMN1; SMN2 4510/4885 |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CSNK1A1, CSK, CSNK1A1L | DNM1 3157/4885TSHR 3447/4885SMN1; SMN2 1173/4885 |
| US-20230295215-A1 | NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | RNGTT, RNMT, NSUN3 | DNM1 1946/4885TSHR 3161/4885SMN1; SMN2 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.